We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Moderna Inc | LSE:0A45 | London | Ordinary Share | MODERNA ORD SHS |
Bid Price | Offer Price | High Price | Low Price | Open Price | |
---|---|---|---|---|---|
76.50 | 80.42 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
- |
Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
---|---|---|---|---|
18:51:48 | O | 1 | 133.26 | USD |
Date | Time | Source | Headline |
---|---|---|---|
23/4/2024 | 06:27 | ALNC | Moderna, Pfizer/BioNTech set for UK court clash over Covid jab patents |
26/3/2024 | 11:00 | UK RNS | Moderna Inc Moderna Achieves Positive Interim Results in Trial |
15/12/2023 | 08:41 | ALNC | Merck gets US FDA nod for Welireg, as trial with Moderna bears fruit |
14/12/2023 | 11:45 | ALNC | Moderna CEO Bancel says melanoma vaccine could be available by 2025 |
11/12/2023 | 17:56 | ALNC | Merck reports mixed updates for cancer treatment, Keytruda |
07/12/2023 | 12:00 | RNSNON | Moderna Inc Moderna Reviews Progress at ESG Investor Event |
30/10/2023 | 07:00 | RNSNON | Moderna Inc CEPI & Moderna Harness MRNA to Advance Mission |
14/9/2023 | 15:16 | RNSNON | Moderna Inc EMA Adopts Positive Opinion of Covid-19 Vaccine |
12/9/2023 | 08:04 | ALNC | US FDA approves updated Covid vaccines from Pfizer and Moderna |
05/7/2023 | 13:27 | ALNC | Moderna submits global regulatory submission for respiratory vaccine |
Moderna (0A45) Share Charts1 Year Moderna Chart |
|
1 Month Moderna Chart |
Intraday Moderna Chart |
Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
---|---|---|---|---|
2024-05-17 18:12:28 | 132.65 | 1,000 | 0.00 | O |
2024-05-17 18:08:03 | 132.38 | 100 | 0.00 | O |
2024-05-17 18:07:53 | 132.32 | 44 | 0.00 | O |
2024-05-17 18:07:39 | 132.34 | 1 | 0.00 | O |
2024-05-17 18:07:32 | 132.43 | 60 | 0.00 | O |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions